790223-53-9

Upstream product

• 790223-47-1 ethyl (R,E)-4-((tert-butoxycarbonyl)amino)-5-phenylpent-2-enoate 
• 104-53-0 3-phenyl-propionaldehyde 
• 1569092-93-8 ethyl (R,E)-4-((tert-butoxycarbonyl)(hydroxy)amino)-5-phenylpent-2-enoate 
• 36016-38-3 tert-Butyl N-hydroxycarbamate 
• 77119-85-8 N-(tert-butoxycarbonyl)-D-phenylalaninal 

Downstream Products

• 1226859-85-3 (S)-5-ethoxy-5-oxo-1-phenylpentan-2-aminium chloride 

Relevant academic research and scientific papers

Consequence of Hapten Stereochemistry: An Efficacious Methamphetamine Vaccine

Recent trends in methamphetamine (METH) misuse and overdose suggest society is inadvertently overlooking a brewing METH crisis. In the past decade, psychostimulant-related lethal overdoses and hospitalizations have skyrocketed 127 and 245%, respectively. Unlike the opioid crisis, no pharmaceutical interventions are available for treating METH use disorder or reversing overdose. Herein, we report the first active vaccine that offers protection from lethal (+)-METH challenge in male Swiss Webster mice. This vaccine formulation of (S)MLMH-TT adjuvanted with CpG ODN 1826 + alum successfully raised anti-METH antibodies in high titers, reduced (+)-METH distribution to the brain, and lowered (+)-METH-associated stereotypies in a hyperlocomotion assay. A comparison of enantiomeric haptens and the racemate elucidated the importance of employing (S)-stereochemistry in METH hapten design for optimal protection.

Practical approach for asymmetric hydroxyamination of aldehydes with in situ generated nitrosocarbonyl compounds: Application to one-pot synthesis of chiral allylamines

The highly regio- and enantioselective hydroxyamination of aldehydes with in situ generated nitrosocarbonyl compounds from a hydroxamic acid derivative was realized by simple and readily available chiral amine catalysts. The resulting hydroxyamination products were readily converted to the corresponding chiral 1,2-aminoalcohol or allylamine derivatives in one pot.

Structure-activity relationships of 6-Methyl-benzo[ b ]thiophene-2- carboxylic Acid (1-{(S)-1-Benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1- yl]butylcarbamoyl}cyclopentyl)amide, potent antagonist of the neurokinin-2 receptor

As part of a project aimed at the identification of a series of small, orally available antagonists for the hNK2 receptor, starting from one of our capped dipeptide libraries, we succeeded in the chemical optimization of the first identified leads, finally producing a class of molecules with significant activity in our animal model after iv administration. We herein report the results of further chemical modifications made to reduce the overall peptide character of this series and the consequent improvement of their in vivo antagonist activity. The present work identified 6-methylbenzo[b]thiophene-2- carboxylic acid (1-{(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1- yl]butylcarbamoyl}cyclopentyl)amide (10i), endowed with subnanomolar potency in all the in vitro tests and being highly potent and of long duration upon in vivo testing after both iv and id dosing.

NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM

The present invention describes compounds with formula (I) having linear structure basic properties useful as NK-2 antagonists; pharmaceutical compositions containing said compounds are also described and processes for their preparation.